Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...

WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Aclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...

In a report released yesterday, Christopher Raymond from Piper Sandler upgraded Aclaris Therapeutics (ACRS – Research Report) to a Buy, with a ...

Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...

Leerink upgraded Aclaris Therapeutics (ACRS) to Outperform from Market Perform with a price target of $7, up from $2, representing over 120% ...

Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...

- 博奥信将获得超过4000万美元的现金付款，作为首付款以及承担部分开发成本和药物产品材料费用，同时博奥信还将获得 Aclaris Therapeutics 19.9% ...

Leerink Partners has recently raised Aclaris Therapeutics Inc (ACRS) stock to Outperform rating, as announced on Today, according to Finviz. Earlier, on Today, Jefferies had raised the stock from a ...

周二，Jefferies分析师将Aclaris Therapeutics Inc. (NASDAQ:ACRS)的股票评级从"持有"上调至"买入"。分析师还大幅提高了该公司股票的目标价，将其从之前的$2.00上调至$7.00。 此次上调是在分析师与公司管理层讨论了其药物候选BSI-045B后做出的。该药物在特应性皮炎(AD)的临床概念验证(POC)中表现出了前景。 该药物独特的结合特性被认为是其潜在 ...

On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...